The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
LYNPARZA AstraZeneca Pty Ltd
Product name
LYNPARZA
Sponsor
Accepted date
Jan-2024
Active ingredients
olaparib
Proposed indication
Indicated for the maintenance treatment of advanced or recurrent endometrial cancer.
Application type
C (new indication)
Publication date
Jan-2024